Nature Communications (Mar 2022)
Ultrasound-controllable engineered bacteria for cancer immunotherapy
Abstract
Synthetic biology has enabled the design of strategies for bacteria-based cancer immunotherapy. Here the authors report the development of focused ultrasound-activatable therapeutic bacteria engineered to express anti-CTLA-4 and anti-PD-L1 nanobodies for cancer immunotherapy.